M&A Deal Summary

Alkermes Acquires Rodin Therapeutics

On November 18, 2019, Alkermes acquired life science company Rodin Therapeutics for 100M USD

Acquisition Highlights
  • This is Alkermes’ 1st transaction in the Life Science sector.
  • This is Alkermes’ largest (disclosed) transaction.
  • This is Alkermes’ 1st transaction in the United States.
  • This is Alkermes’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2019-11-18
Target Rodin Therapeutics
Sector Life Science
Buyer(s) Alkermes
Deal Type Add-on Acquisition
Deal Value 100M USD
Advisor(s) Goodwin Procter (Legal)

Target

Rodin Therapeutics

Boston, Massachusetts, United States
Rodin Therapeutics, Inc. is a biopharmaceutical company discovering and developing first-in-class therapeutics by applying novel chemical strategies to target protein complexes that selectively modulate gene expression. Rodin Therapeutics is based in Boston, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alkermes

Dublin, Ireland
Category Company
Founded 1987
Sector Life Science
Employees2,100
Revenue 1.7B USD (2023)
DESCRIPTION

Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases and oncology. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for diseases that include schizophrenia, depression, addiction, multiple sclerosis, and cancer. Alkermes was founded in 1987 and is based in Dublin, Ireland.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal